Merck & Co. Inc. received FDA clearance of its nine-valent HPV vaccine, Gardasil 9, on Dec. 10, but it’s unclear whether the additional HPV protection offered by the vaccine can help the company and the Center for Disease Control and Prevention overcome the hurdles to widespread vaccination, many of which may be cultural, not scientific.
Gardasil 9 covers five more human papillomavirus types (31, 33, 45, 52 and 58) than Merck’s original Gardasil vaccine approved...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?